Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dyne Therapeutics (DYN)
NASDAQ:DYN
Holding DYN?
Track your performance easily
DYN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.12 - $47.45
Previous Close$29.45
Volume257.28K
Average Volume (3M)1.29M
Market Cap
$2.95B
Enterprise Value$2.30B
Total Cash (Recent Filing)$723.67M
Total Debt (Recent Filing)$24.86M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Feb 27, 2025EPS Estimate
-$0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.56
Shares Outstanding101,765,958
10 Day Avg. Volume1,309,733
30 Day Avg. Volume1,292,717
Standard Deviation0.22
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.32
Forecast
1Y Price Target
$49.29Price Target Upside70.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Dyne Therapeutics News
PremiumCompany Announcements
Dyne Therapeutics Reveals Q3 Results and Trial Updates
Bulls Say, Bears Say
Bulls Say
Accelerated Approval PathwayDyne has begun enrolling a 20 mg/kg registrational cohort for DELIVERY, which may allow the company to pursue accelerated approval for their treatment.
Regulatory MilestonesThe FDA has cleared the IND application for DYNE-101, which is a positive regulatory milestone for the company.
Safety And EfficacyDyne's data shows one of the highest levels of dystrophin expression seen so far, indicating strong efficacy compared to existing treatments.
Bears Say
Efficacy DoubtsA dose-dependent effect was not clearly visible in most of the functional endpoints including Stride Velocity 95th Centile (SV95C), timed rise from floor, and timed 10-meter walk/run test at the 6 month mark.
Management InstabilityThe company announced the departure of 3 senior executives, the CMO, COO, and CBO.
Safety ConcernsThe tradeoff of magnitude of increased dystrophin expression vs the potential safety risk now appears less favorable.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DYN FAQ
What was Dyne Therapeutics’s price range in the past 12 months?
Dyne Therapeutics lowest stock price was $10.12 and its highest was $47.45 in the past 12 months.
What is Dyne Therapeutics’s market cap?
Currently, no data Available
When is Dyne Therapeutics’s upcoming earnings report date?
Dyne Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 92 days.
How were Dyne Therapeutics’s earnings last quarter?
Dyne Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.712 by -$0.248.
Is Dyne Therapeutics overvalued?
According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued.
Does Dyne Therapeutics pay dividends?
Dyne Therapeutics does not currently pay dividends.
What is Dyne Therapeutics’s EPS estimate?
Dyne Therapeutics’s EPS estimate is -$0.94.
How many shares outstanding does Dyne Therapeutics have?
Dyne Therapeutics has 101,765,960 shares outstanding.
What happened to Dyne Therapeutics’s price movement after its last earnings report?
Dyne Therapeutics reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.712. Following the earnings report the stock price went up 4.266%.
Which hedge fund is a major shareholder of Dyne Therapeutics?
Among the largest hedge funds holding Dyne Therapeutics’s share is RA Capital Management. It holds Dyne Therapeutics’s shares valued at 229M.
---
Dyne Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.29 (70.05% Upside)
$49.29 (70.05% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.3%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
166.51%
12-Months-Change
Fundamentals
Return on Equity
-68.69%
Trailing 12-Months
Asset Growth
274.60%
Trailing 12-Months
Company Description
Dyne Therapeutics
Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
---
DYN Stock 12 Month Forecast
Average Price Target
$49.29
▲(70.05% Upside)
Technical Analysis
Scholar Rock Holding
―
Rocket Pharmaceuticals
―
Wave Life Sciences
―
Fulcrum Therapeutics
―
Best Analysts Covering DYN
1 Year
1 Year Success Rate
9/12 ratings generated profit
1 Year Average Return
+67.36%
reiterated a buy rating 3 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +67.36% per trade.
---